Here are the 10-K annual reports from GeneDx Holdings Corp. (WGS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow WGS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full WGS filings page.
GeneDx Holdings Corp. files its annual report describing a genomics business built around exome and whole genome sequencing, including ExomeDx™ and GenomeDx™ tests that hold FDA Breakthrough Device Designation. The company emphasizes one of the world’s largest rare disease datasets, with over 2.5 million tests, including more than 1 million exomes and genomes, and a high proportion of non‑European samples.
Growth priorities focus on pediatric outpatient genetics, NICU rapid genomes, prenatal testing and genomic newborn screening through studies such as GUARDIAN, BEACONS and SeqFirst, plus international expansion via the 2025 Fabric Genomics acquisition. The report details a heavily regulated environment, reimbursement dependence, intense competition, extensive use of AI for interpretation, and broad U.S. and international privacy, laboratory, and fraud‑and‑abuse compliance obligations.